Retrophin Company Profile (NASDAQ:RTRX)

About Retrophin (NASDAQ:RTRX)

Retrophin logoRetrophin, Inc. is a biopharmaceutical company. The Company is focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. The Company sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin). Its Chenodal is approved in the United States for the treatment of patients suffering from gallstones in whom surgery poses an unacceptable health risk due to disease or advanced age. Chenodal has also been care for cerebrotendinous xanthomatosis (CTX) patients. Its Cholbam is approved in the United States for the treatment of bile acid synthesis disorders due to single enzyme defects and is further indicated for adjunctive treatment of patients with peroxisomal disorders. Its Thiola is approved in the United States for the prevention of cystine (kidney) stone formation in patients with severe homozygous cystinuria.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Manufacturers - Major
  • Sub-Industry: N/A
  • Symbol: NASDAQ:RTRX
  • CUSIP: N/A
  • Web:
  • Market Cap: $644.74 million
  • Outstanding Shares: 38,173,000
Average Prices:
  • 50 Day Moving Avg: $18.21
  • 200 Day Moving Avg: $19.39
  • 52 Week Range: $15.88 - $24.57
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -11.81
  • P/E Growth: -0.79
Sales & Book Value:
  • Annual Revenue: $138.2 million
  • Price / Sales: 4.67
  • Book Value: $7.89 per share
  • Price / Book: 2.14
  • EBIDTA: ($23,610,000.00)
  • Net Margins: -32.96%
  • Return on Equity: -1.33%
  • Return on Assets: -0.79%
  • Debt-to-Equity Ratio: 0.14%
  • Current Ratio: 3.98%
  • Quick Ratio: 3.95%
  • Average Volume: 375,803 shs.
  • Beta: 1.12
  • Short Ratio: 11.48

Frequently Asked Questions for Retrophin (NASDAQ:RTRX)

What is Retrophin's stock symbol?

Retrophin trades on the NASDAQ under the ticker symbol "RTRX."

How were Retrophin's earnings last quarter?

Retrophin Inc (NASDAQ:RTRX) issued its earnings results on Thursday, May, 4th. The company reported $0.01 earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.22) by $0.23. The business had revenue of $33.62 million for the quarter, compared to the consensus estimate of $36.20 million. Retrophin had a negative net margin of 32.96% and a negative return on equity of 1.33%. The firm's revenue for the quarter was up 15.9% on a year-over-year basis. During the same period in the previous year, the company earned $0.14 earnings per share. View Retrophin's Earnings History.

Where is Retrophin's stock going? Where will Retrophin's stock price be in 2017?

4 brokerages have issued 1-year price objectives for Retrophin's stock. Their predictions range from $28.00 to $45.00. On average, they expect Retrophin's share price to reach $35.00 in the next year. View Analyst Ratings for Retrophin.

What are analysts saying about Retrophin stock?

Here are some recent quotes from research analysts about Retrophin stock:

  • 1. According to Zacks Investment Research, "Retrophin is a pharmaceutical company focused on the development, acquisition and commercialization of drugs for the treatment of serious, catastrophic or rare diseases for which there are currently no viable options for patients. The Company's approved products include Chenodal®, Cholbam, and Thiola®, and its pipeline includes compounds for several catastrophic diseases, including focal segmental glomerulosclerosis, pantothenate kinase-associated neurodegeneration, infantile spasms, nephrotic syndrome and others. Retrophin, Inc. is based in San Diego. " (5/3/2017)
  • 2. BMO Capital Markets analysts commented, "We maintain our Outperform rating on RTRX shares following Retrophin's announcement to initiate a Phase III trial in 2H17 for Sparsentan. Our price target decreases to $45 from $46, as we push back Sparsentan estimates by two years, but increase our probability of success to 75% from 55%. We believe FDA agreement for proteinuria as an approvable endpoint removes significant uncertainty around Sparsentan's regulatory path as well as avoids a lengthy trial requiring eGFR or kidney survival as endpoints. We estimate Sparsentan peak sales (US only) of $1bn." (3/2/2017)

Who are some of Retrophin's key competitors?

Who owns Retrophin stock?

Retrophin's stock is owned by many different of retail and institutional investors. Top institutional investors include Broadfin Capital LLC (7.58%), Perceptive Advisors LLC (7.35%), FMR LLC (5.14%), Jennison Associates LLC (4.83%), Vanguard Group Inc. (3.96%) and State Street Corp (3.15%). Company insiders that own Retrophin stock include Alvin Shih, Jeffrey A Meckler, Jensen Margaret E Valeur and Steve Aselage. View Institutional Ownership Trends for Retrophin.

Who sold Retrophin stock? Who is selling Retrophin stock?

Retrophin's stock was sold by a variety of institutional investors in the last quarter, including Broadfin Capital LLC, Jennison Associates LLC, Morgan Stanley, Signpost Capital Advisors LP, American Century Companies Inc., Oxford Asset Management, Geode Capital Management LLC and Round Table Services LLC. Company insiders that have sold Retrophin stock in the last year include Alvin Shih and Steve Aselage. View Insider Buying and Selling for Retrophin.

Who bought Retrophin stock? Who is buying Retrophin stock?

Retrophin's stock was bought by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., TIAA CREF Investment Management LLC, FMR LLC, Renaissance Technologies LLC, Dimensional Fund Advisors LP, JPMorgan Chase & Co., Spark Investment Management LLC and Perceptive Advisors LLC. View Insider Buying and Selling for Retrophin.

How do I buy Retrophin stock?

Shares of Retrophin can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Retrophin stock cost?

One share of Retrophin stock can currently be purchased for approximately $16.89.

Analyst Ratings

Consensus Ratings for Retrophin (NASDAQ:RTRX) (?)
Ratings Breakdown: 4 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $35.00 (107.22% upside)

Analysts' Ratings History for Retrophin (NASDAQ:RTRX)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
4/6/2017William BlairReiterated RatingOutperformMediumView Rating Details
3/2/2017BMO Capital MarketsLower Price TargetOutperform$46.00 -> $45.00N/AView Rating Details
12/15/2016JMP SecuritiesSet Price TargetBuy$28.00N/AView Rating Details
9/7/2016Leerink SwannBoost Price TargetOutperform$27.00 -> $32.00N/AView Rating Details
6/4/2015Deutsche Bank AGBoost Price TargetBuy$52.00 -> $55.00N/AView Rating Details
(Data available from 5/24/2015 forward)


Earnings History for Retrophin (NASDAQ:RTRX)
Earnings by Quarter for Retrophin (NASDAQ:RTRX)
Earnings History by Quarter for Retrophin (NASDAQ:RTRX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/4/2017Q1 2017($0.22)$0.01$36.20 million$33.62 millionViewListenView Earnings Details
11/3/2016Q3$0.38($0.09)$34.84 million$33.95 millionViewN/AView Earnings Details
5/3/2016Q1($0.22)$0.14$31.00 million$29.00 millionViewN/AView Earnings Details
2/25/2016Q4($0.22)$0.07$29.40 million$30.40 millionViewListenView Earnings Details
11/3/2015Q3$0.09($0.04)$27.35 million$28.00 millionViewN/AView Earnings Details
8/4/2015Q215($0.42)$0.40$20.52 million$24.10 millionViewN/AView Earnings Details
5/11/2015Q115($0.50)($0.04)$17.23 million$17.37 millionViewListenView Earnings Details
3/5/2015Q414($0.36)$14.10 millionViewListenView Earnings Details
11/13/2014Q3($0.53)$8.35 millionViewListenView Earnings Details
8/12/2014Q214($0.52)$5.74 millionViewN/AView Earnings Details
5/14/2014Q114($0.44)($3.03)$0.80 million$0.03 millionViewListenView Earnings Details
3/27/2014($0.30)($0.76)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Retrophin (NASDAQ:RTRX)
2017 EPS Consensus Estimate: ($0.91)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.25)($0.19)($0.22)
Q2 20172($0.25)($0.19)($0.22)
Q3 20172($0.28)($0.18)($0.23)
Q4 20172($0.30)($0.17)($0.24)
(Data provided by Zacks Investment Research)


Dividend History for Retrophin (NASDAQ:RTRX)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Retrophin (NASDAQ:RTRX)
Insider Ownership Percentage: 2.41%
Insider Trades by Quarter for Retrophin (NASDAQ:RTRX)
Institutional Ownership by Quarter for Retrophin (NASDAQ:RTRX)
Insider Trades by Quarter for Retrophin (NASDAQ:RTRX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/22/2016Steve AselageCEOSell8,200$21.12$173,184.00View SEC Filing  
9/1/2016Alvin ShihEVPSell8,750$16.24$142,100.00View SEC Filing  
6/1/2016Alvin ShihEVPSell8,750$17.75$155,312.50View SEC Filing  
3/4/2016Jeffrey A MecklerDirectorBuy5,000$15.31$76,550.00View SEC Filing  
3/3/2016Jeffrey A MecklerDirectorBuy10,000$14.45$144,500.00View SEC Filing  
3/1/2016Alvin ShihEVPSell8,750$14.35$125,562.50View SEC Filing  
12/9/2015Alvin ShihEVPSell8,750$20.83$182,262.50View SEC Filing  
11/2/2015Jensen Margaret E. ValeurGeneral CounselSell50,000$20.46$1,023,000.00View SEC Filing  
10/6/2015Alvin ShihEVPSell8,750$20.12$176,050.00View SEC Filing  
6/26/2015Alvin ShihEVPSell27,916$32.70$912,853.20View SEC Filing  
12/12/2014Horacio PlotkinInsiderSell2,100$10.07$21,147.00View SEC Filing  
11/25/2014Jeffrey A MecklerDirectorBuy15,000$8.60$129,000.00View SEC Filing  
11/21/2014Martin ShkreliInsiderSell1,172,000$8.84$10,360,480.00View SEC Filing  
11/21/2014Steve AselageCEOBuy10,000$8.46$84,600.00View SEC Filing  
11/21/2014Steven Gary RichardsonDirectorBuy6,100$8.38$51,118.00View SEC Filing  
11/19/2014Cornelius E GoldingDirectorBuy2,000$9.00$18,000.00View SEC Filing  
9/30/2014Martin ShkreliCEOBuy4,000$9.42$37,680.00View SEC Filing  
9/22/2014Martin ShkreliCEOBuy53,000$11.15$590,950.00View SEC Filing  
9/17/2014Martin ShkreliCEOBuy6,000$11.46$68,760.00View SEC Filing  
9/16/2014Martin ShkreliCEOBuy7,500$10.69$80,175.00View SEC Filing  
4/4/2014Martin ShkreliCEOBuy8,000$19.64$157,120.00View SEC Filing  
4/3/2014Martin ShkreliCEOBuy22,500$22.60$508,500.00View SEC Filing  
4/2/2014Martin ShkreliCEOBuy10,800$22.28$240,624.00View SEC Filing  
3/24/2014Martin ShkreliCEOBuy4,000$17.61$70,440.00View SEC Filing  
3/20/2014Martin ShkreliCEOBuy5,000$17.97$89,850.00View SEC Filing  
3/19/2014Martin ShkreliCEOBuy3,500$18.44$64,540.00View SEC Filing  
3/14/2014Martin ShkreliCEOBuy4,000$17.36$69,440.00View SEC Filing  
3/11/2014Martin ShkreliCEOBuy25,900$19.47$504,273.00View SEC Filing  
3/10/2014Martin ShkreliCEOBuy10,700$19.32$206,724.00View SEC Filing  
3/7/2014Martin ShkreliCEOBuy4,058$18.52$75,154.16View SEC Filing  
3/5/2014Martin ShkreliCEOBuy4,000$18.48$73,920.00View SEC Filing  
2/28/2014Martin ShkreliCEOBuy43,100$18.66$804,246.00View SEC Filing  
2/21/2014Martin ShkreliCEOBuy1,600$17.56$28,096.00View SEC Filing  
2/14/2014Martin ShkreliCEOBuy3,500$14.60$51,100.00View SEC Filing  
2/6/2014Martin ShkreliCEOBuy2,000$9.92$19,840.00View SEC Filing  
1/14/2014Martin ShkreliCEOBuy8,000$10.84$86,720.00View SEC Filing  
12/31/2013Martin ShkreliCEOBuy150,000$7.00$1,050,000.00View SEC Filing  
12/24/2013Cornelius E GoldingDirectorBuy3,000$7.50$22,500.00View SEC Filing  
11/5/2013Steven Gary RichardsonDirectorBuy2,900$6.90$20,010.00View SEC Filing  
9/12/2013Martin ShkreliCEOBuy11,112$4.50$50,004.00View SEC Filing  
8/22/2013Martin ShkreliCEOBuy3,900$6.06$23,634.00View SEC Filing  
8/15/2013Horacio PlotkinInsiderBuy2,200$4.50$9,900.00View SEC Filing  
8/15/2013Marc L PanoffCFOBuy1,100$4.50$4,950.00View SEC Filing  
3/4/2013Martin ShkreliCEOBuy1,000$4.43$4,430.00View SEC Filing  
2/20/2013Martin ShkreliCEOBuy1,120$4.16$4,659.20View SEC Filing  
2/14/2013Martin ShkreliCEOBuy120,000$3.00$360,000.00View SEC Filing  
2/12/2013Martin ShkreliCEOBuy1,400$3.57$4,998.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Retrophin (NASDAQ:RTRX)
Latest Headlines for Retrophin (NASDAQ:RTRX)
DateHeadline logoRetrophin to Present at the Jefferies 2017 Global Healthcare Conference - May 23 at 6:59 PM logoTheStreet Upgrades Retrophin Inc (RTRX) to "C-" - May 17 at 2:50 PM logoETFs with exposure to Retrophin, Inc. : May 12, 2017 - May 12 at 10:59 PM logoRetrophin Inc (RTRX) Expected to Announce Quarterly Sales of $36.71 Million - May 11 at 9:38 AM logoRetrophin, Inc. :RTRX-US: Earnings Analysis: Q1, 2017 By the Numbers : May 10, 2017 - May 10 at 7:51 PM logoZacks: Analysts Expect Retrophin Inc (RTRX) to Post -$0.24 EPS - May 10 at 12:12 AM logoEdited Transcript of RTRX earnings conference call or presentation 4-May-17 8:30pm GMT - May 5 at 7:58 PM logoRetrophin Inc (RTRX) Releases Quarterly Earnings Results, Beats Estimates By $0.23 EPS - May 5 at 5:30 PM logoRetrophin's (RTRX) CEO Steve Aselage on Q1 2017 Results - Earnings Call Transcript - May 5 at 12:56 AM logoRetrophin Reports First Quarter 2017 Financial Results - May 4 at 7:54 PM logoRetrophin reports 1Q loss - May 4 at 6:57 PM logoRetrophin (RTRX) Given Coverage Optimism Rating of 0.03 - May 3 at 3:05 PM logoRetrophin Inc (RTRX) Downgraded by Zacks Investment Research - May 3 at 9:34 AM logoRetrophin Inc (RTRX) Receives Consensus Recommendation of "Buy" from Analysts - May 3 at 12:30 AM logoFavorable Media Coverage Extremely Likely to Affect Retrophin (RTRX) Share Price - April 30 at 2:41 PM logoRetrophin Inc (RTRX) to Release Quarterly Earnings on Monday - April 29 at 7:36 AM logoRetrophin, Inc. – Value Analysis (NASDAQ:RTRX) : April 27, 2017 - April 27 at 8:04 PM logoRetrophin (RTRX) Receiving Somewhat Negative News Coverage, Study Shows - April 27 at 5:45 PM logoRetrophin, Inc. breached its 50 day moving average in a Bullish Manner : RTRX-US : April 26, 2017 - April 26 at 5:36 PM logoPharma bro Martin Shkreli asks judge to order document hand-over, bar other evidence - April 26 at 5:36 PM logoRetrophin (RTRX) Getting Somewhat Favorable News Coverage, Analysis Shows - April 24 at 6:34 PM logoEquities Analysts Offer Predictions for Retrophin Inc's FY2019 Earnings (RTRX) - April 21 at 5:32 PM logoRetrophin (RTRX) Earns Media Sentiment Score of -0.03 - April 20 at 8:35 PM logoRetrophin to Report First Quarter 2017 Financial Results - April 20 at 7:43 PM logoRetrophin Inc (RTRX) Expected to Post Earnings of -$0.22 Per Share - April 19 at 7:54 AM logoRetrophin (RTRX) Given Media Impact Rating of 0.28 - April 16 at 2:15 PM logoRetrophin (RTRX) Receives News Sentiment Rating of 0.01 - April 13 at 3:50 PM logoRetrophin (RTRX) Names Ron Squarer to Board of Directors - - April 12 at 11:24 PM logoRetrophin Appoints Ron Squarer to Board of Directors - GlobeNewswire (press release) - April 12 at 6:22 PM logoEndo (ENDP) Reports Preliminary Results for First Quarter - April 11 at 7:26 PM logoRetrophin Inc Forecasted to Earn Q1 2017 Earnings of ($0.25) Per Share (RTRX) - April 10 at 7:10 AM logoRetrophin Inc (RTRX) Given Consensus Rating of "Buy" by Analysts - April 6 at 5:15 PM logoRetrophin Inc (RTRX) Now Covered by William Blair - April 6 at 2:16 PM logoRetrophin Inc (RTRX) Short Interest Down 0.3% in March - April 6 at 1:28 PM logoBioDelivery to Grant New Patents for its Marketed Drugs - April 3 at 8:46 AM logoWill Endo's Troubles Continue to Dent Performance in 2017? - March 28 at 7:28 PM logoRETROPHIN, INC. Files SEC form 8-K, Change in Directors or Principal Officers - March 27 at 6:52 PM logoRetrophin (RTRX) Appoints John Orwin to Board of Directors - March 23 at 8:06 PM logoAlexion (ALXN) Licenses Artubus Technology for Rare Diseases - March 17 at 7:42 PM logoShire's (SHPG) Cinryze Label Expanded for Pediatric Use - March 16 at 8:30 PM logoRetrophin Inc (RTRX) Upgraded to Strong-Buy by Zacks Investment Research - March 13 at 2:48 PM logoMartin Shkreli’s former biotech company Retrophin is leaving Cambridge - March 9 at 7:37 PM logoRETROPHIN, INC. Financials - March 8 at 7:53 PM logoRETROPHIN, INC. Files SEC form 8-K, Costs Associated with Exit or Disposal Activities - March 8 at 7:53 PM logoRetrophin to Present at the Barclays Global Healthcare Conference - March 7 at 7:30 PM logoEdited Transcript of RTRX earnings conference call or presentation 1-Mar-17 10:00pm GMT - March 2 at 8:06 AM logoRetrophin Provides Sparsentan Regulatory Update; Reports Fourth Quarter and Full Year 2016 Financial Results - March 1 at 7:54 PM logoQ4 2016 Retrophin Inc Earnings Release - After Market Close - March 1 at 10:11 AM logoNoteworthy Monday Option Activity: TSLA, RTRX, GME - February 27 at 4:26 PM logoGreebel dubs Shkreli a 'serial liar' - Seeking Alpha - February 23 at 8:13 AM



Retrophin (RTRX) Chart for Wednesday, May, 24, 2017

This page was last updated on 5/24/2017 by Staff